E2F-2 Antibody (H-9): sc-514477

E2F-2 Antibody (H-9) is a mouse monoclonal IgG1 antibody that detects E2F-2 in human samples through applications such as western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and enzyme-linked immunosorbent assay (ELISA). E2F-2 plays a crucial role in regulating the cell cycle, particularly in the transition from the G1 phase to the S phase, by controlling the expression of genes necessary for DNA synthesis and cell proliferation. This regulation is vital for maintaining proper cell growth and division, and dysregulation of E2F-2 can lead to uncontrolled cell proliferation, a hallmark of cancer. E2F-2 is part of a larger family of E2F transcription factors, which interact with the retinoblastoma protein (Rb) to form a transcriptional regulatory complex that is essential for the precise control of cell cycle progression. Formation of heterodimers between E2F-2 and DP-1 protein enhances transcriptional activity, allowing effective regulation of target genes involved in cell cycle control. Anti-E2F-2 antibody (H-9) enables researchers to gain insights into the mechanisms of cell cycle regulation and the potential implications of E2F-2 in oncogenesis.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

E2F-2 Antibody (H-9) References:

1. Specific tumor suppressor function for E2F2 in Myc-induced T cell lymphomagenesis.  |  Opavsky, R., et al. 2007. Proc Natl Acad Sci U S A. 104: 15400-5. PMID: 17881568
2. E2F2 expression induces proliferation of terminally differentiated cardiomyocytes in vivo.  |  Ebelt, H., et al. 2008. Cardiovasc Res. 80: 219-26. PMID: 18628254
3. The E2F2 transcription factor sustains hepatic glycerophospholipid homeostasis in mice.  |  Maldonado, EN., et al. 2014. PLoS One. 9: e112620. PMID: 25396754
4. Increased metastasis with loss of E2F2 in Myc-driven tumors.  |  Yuwanita, I., et al. 2015. Oncotarget. 6: 38210-24. PMID: 26474282
5. miR-638 represses the stem cell characteristics of breast cancer cells by targeting E2F2.  |  Lin, QY., et al. 2020. Breast Cancer. 27: 147-158. PMID: 31410735
6. Selected E2F2 Polymorphisms in Oral and Oropharyngeal Squamous Cell Carcinoma.  |  Gołąbek, K., et al. 2021. Biomed Res Int. 2021: 8098130. PMID: 33860054
7. LncRNA SNHG22 promotes gastric cancer progression by regulating the miR-101-3p/e2f2 axis.  |  Li, Z., et al. 2023. Cell Cycle. 22: 347-360. PMID: 36281526
8. The Potential Association between E2F2, MDM2 and p16 Protein Concentration and Selected Sociodemographic and Clinicopathological Characteristics of Patients with Oral Squamous Cell Carcinoma.  |  Świętek, A., et al. 2023. Curr Issues Mol Biol. 45: 3268-3278. PMID: 37185737
9. Diosmetin suppresses the progression of ESCC by CDK2/Rb/E2F2/RRM2 pathway and synergies with cisplatin.  |  Chen, Y., et al. 2023. Oncogene. 42: 2278-2293. PMID: 37349644
10. DNM3OS Enhances the Apoptosis and Senescence of Spermatogonia Associated with Nonobstructive Azoospermia by Providing miR-214-5p and Decreasing E2F2 Expression.  |  Hua, R., et al. 2023. Anal Cell Pathol (Amst). 2023: 1477658. PMID: 38152068

The preferred E2F-2 antibody is E2F-2 Antibody (TFE-25): sc-9967.